London, 7 November 2022. Sanquin Reagents, headquartered in Amsterdam (NL), produces and sells blood grouping and immune reagents, materials necessary for diagnostic research and drug development. The company has built a brand reputation for high product quality, reliability and innovation, becoming a key partner in developing custom-made reagents for industry-leading diagnostic equipment providers. Supported by Gilde Healthcare, Sanquin Reagents intends to expand its research capabilities and scale up its production of diagnostic tests to further strengthen its leading position in the development of immune reagents.
Jonathan Smith, a Managing Director at LGT Private Debt, said: “We are delighted to arrange a unitranche facility to support Gilde Healthcare in completing the acquisition of Sanquin Reagents, and look forward to continuing to work with them and management. We believe Gilde Healthcare is the right partner to further leverage the company’s research and production capabilities and to accelerate its future growth plans.”
Hugo de Bruin, Partner at Gilde Healthcare, said: “LGT Private Debt has demonstrated its ability to understand the strong potential of Sanquin Reagents, and was committed to delivering a tailor-made financing solution to meet the company’s requirements. We are pleased to team up with a lender engaged with our vision for the future of the company.”